KRAS and lung cancer: Non–small-cell lung cancer with oncogenic K-Ras mutations is refractory to pharmacological treatment targeted to Ras enzymatic activity because mutant K-Ras oncoproteins lack the normal protein’s intrinsic GTPase function.